Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 601–617 of 617
Novel pathological mechanisms support new therapeutic opportunities in Duchenne Muscular Dystrophy
Hong, A. V. (2021) · theses.fr (ABES) · doi:10.70675/b4b906e2zca90z411dzbcc0z6dbdbfb9e0ed · Cited by 1
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Lysosomal defects in Duchenne muscular dystrophy : advancing combined therapeutic approaches
Jaber, A. (2024) · theses.fr (ABES) · doi:10.70675/d5d1c272z2c2cz4571zb9ccz8134fc1276c2
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
CRISPR-Cas-Based Editing Technologies in Preclinical Models for Disease Correction
Karki, P., & Sudarshan, G. C. (2026) · Genetics. · doi:10.5772/intechopen.1015771 · Cited by 1
Clinical, pathological, and genetic characteristics of 23 DMD patients in northern China
Bu, Y., Han, J., Deng, J., Fang, P., An, D., Ji, G., Ma, S. Q., & Song, X. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04488-y
“In such cases, some oocytes carry a mutated X chromosome, and the risk of affected male offspring depends on the proportion of mutant germ cells in the mother [2, 16].”
Stenler, S., Huang, J., van Westering, T. L. E., Coenen-Stass, A. M. L., Jad, Y. E., Krjutškov, K., Andaloussi, S. E., Wood, M. J. A., & Roberts, T. C. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103017
“Exon skipping splice correction and microdystrophin gene therapies both rely on the generation of internally deleted quasi-dystrophin proteins that resemble those found in some patients with Becker muscular dystrophy, 55 and which are associated with mild pathology.”
abdelnaby, M., Galiakberova, A. A., & Dashinimaev, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156846
“This constraint is particularly relevant for genes such as full-length dystrophin (~11.4 kb) in Duchenne muscular dystrophy and CEP290 (~7.5 kb) in Leber congenital amaurosis type 10, both of which substantially exceed this packaging threshold [90].”
InfluentialGeoffroy, M., Beley, C., Campuzano, S., Nguyen, T. H., Schmidt, L. M., Blaszykowski, C., Krüger, M., Garcı́a, L., & Guiraud, S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103048
Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2733200
“Their design was informed by mild Becker muscular dystrophy associated with large in frame deletions and by subsequent structure and function studies [36,37].”
Guiraud, S., Edwards, B., Squire, S. E., & Davies, K. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750746
Self-citationNassour, H., Al_Shbailat, S. A., Ibrahim, A. S., Allan, A. M., Badie, M. S., Alnjoom, Q. M., Alrfou, M. J. F., Makhoul, G. E., Weis, M. G., Ahmad, R. K., et al. (2026) · Journal of Medical Genetics · doi:10.1136/jmg-2026-111649
Gene therapy in Duchenne muscular dystrophy (DMD)
Azizsoltani, A., Ghesmati, Z., & Rezaei, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00006-3
Li, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
“Genotype–phenotype data from Becker muscular dystrophy and transgenic studies indicated that dystrophin retains meaningful function after substantial internal deletion, provided key structural elements are preserved (England et al., 1990; Phelps et al., 1995).”
Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy
Harris, B. E., Seldin, B. M., Towne, S. C., Hobson, O. R., Zerpa, E., Prima, V., Sweeney, H. L., & Hammers, D. W. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1953867
“The goal of this treatment is to transform DMD to a slower progressing disease that resembles milder forms of muscular dystrophy (England et al., 1990).”
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.